Guardant Health

By ringing this morning's bell, we celebrate another pivotal moment in our journey to conquer cancer with data with the FDA approval and commercial launch of our Shield blood test! Thank you to our dedicated team, partners, and supporters who have made this achievement possible. Watch the opening ceremony: https://lnkd.in/gRGepS_c

Today we announced that we will proudly ring the Nasdaq opening bell on August 28 to celebrate the launch of our Shield blood test for colorectal cancer screening. “We recently launched Shield, our FDA-approved blood-based screening test, marking a pivotal moment on our journey to conquer cancer with data. We are thrilled to commemorate this important milestone by ringing the Nasdaq bell, nearly six years after we first rang the bell for our IPO,” - co-CEO AmirAli Talasaz. Watch the bell ringing live next Wednesday at 8:30am ET: https://bit.ly/470NlnO

Last week, our teams came together for a fantastic “Making History” event, where we celebrated two major milestones: the upgrade of Guardant360 on our Infinity platform and the FDA approval of our Shield blood test. A heartfelt THANK YOU to every Guardant employee. Your dedication and teamwork are the driving force behind our success. As AmirAli Talasaz shared, while each of our roles may vary, our collective innovation, grit, and courage shine brightest when we unite as #OneGuardant.

Our oncology sales team is growing! https://bit.ly/3SIotej At Guardant Health, our cutting-edge solutions place us at the forefront of cancer care. As we continue to make significant breakthroughs with our market-leading liquid biopsy testing, we’re expanding our presence across several U.S. regions. We’re looking for passionate sales professionals who embrace our patient-first approach to help individuals receive the right treatment plan. Sound exciting? #JoinGuardant and help us conquer cancer with data!

A more pleasant way to screen for colon cancer deserves a pleasant website experience.   Introducing ShieldCancerScreen.com—your go-to source to learn more about Shield and access valuable resources. Explore how we’re transforming #ColorectalCancer screening with our FDA-approved Shield test today!

Today we announced our second quarter financial results and updated guidance for the year.

Our COSMOS study was published today in Clinical Cancer Research, a journal of the American Association for Cancer Research. The results validate the utility of our Guardant Reveal blood test for predicting colorectal cancer recurrence without the complexity of prior tissue analysis.

The Guardant IP legal team, together with leaders from our research and development teams, recently hosted the United States Patent and Trademark Office (USPTO) as part of their Site Experience Education (SEE) Program.   The visit provided a valuable platform for us to showcase our groundbreaking work and engage in meaningful dialogue with USPTO officials and we look forward to continued conversations.

Our Shield blood test is now covered by Medicare and is commercially available in the U.S. as the first FDA-approved blood test for primary #ColorectalCancer (CRC) screening. Our co-CEO AmirAli Talasaz: “From day one, Shield will be covered for more than 45 million Medicare beneficiaries… This is a major step forward in the fight against colorectal cancer and a significant opportunity for Guardant Health.”

Today we announced our health outcomes study, the CAN-SCREEN model, has been accepted for publication in the Journal of Medical Economics. The study highlights the importance of combining clinically meaningful screening performance with high patient adherence in colorectal cancer screening to optimize CRC-related health outcomes.